Analytical Data
-
Gene name
KIF14
- Application
-
Alternative Names
KIF14；KIAA0042；Kinesin-like Protein KIF14
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q15058
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KIF14, a member of the kinesin superfamily of motor proteins, plays a crucial role in cellular processes such as mitosis, cell division, and intracellular transport. It is essential for the proper alignment and separation of chromosomes during cell division, which is vital for maintaining genomic stability. Aberrant expression or dysfunction of KIF14 has been implicated in various cancers, making it a significant target for cancer research. The investigation of KIF14 recombinant protein facilitates the understanding of its structure-function relationship, as well as its interactions with other cellular components. By producing KIF14 in a recombinant form, researchers can analyze its biochemical properties, determine its role in cellular processes, and explore its potential as a therapeutic target. The use of recombinant technologies allows for the production of large quantities of KIF14, enabling detailed studies of its enzymatic activity, subcellular localization, and the effects of post-translational modifications. As cancer therapy increasingly focuses on targeting specific molecular pathways, understanding KIF14's functional mechanisms could provide insights into novel treatment strategies and contribute to the development of targeted therapies aimed at inhibiting its activity in malignant cells.
